Aligos Therapeutics Inc expected to post a loss of $2.50 a share - Earnings Preview

Aligos Therapeutics

07/03/2025 12:44

Aligos Therapeutics Inc ALGS.OQ ALGS.O is expected to show a fall in quarterly revenue when it reports  results on March 10 for the period ending December 31 2024

The South San Francisco California-based  company is expected to report a 78.4% decrease in revenue to $433.33 thousand from $2.01 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Aligos Therapeutics Inc is for a loss of $2.50 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Aligos Therapeutics Inc is $67.50​, above​ its last closing price of $13.48. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-2.47
-2.16
-3.07
Missed
-42.3
Jun. 30 2024
-4.00
-4.00
0.80
Beat
120
Mar. 31 2024
-4.75
-4.75
-5.50
Missed
-15.8​
Dec. 31 2023
-2.75
-6.75
-5.50
Beat
18.5
​​Sep. 30 2023
-11.73
-11.87
-10.25
Beat
13.7
Jun. 30 2023
-12.19
-12.37
-10.75
Beat
13.1​
Mar. 31 2023
-11.93
-12.12
-13.25
Missed
-9.3
Dec. 31 2022
-11.45
-11.80
-12.75
Missed
-8.1

This summary was machine generated March 7 at 12:44 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)